Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Effect of Surface EMG Biofeedback on Quadriceps Inhibition Release During Postoperative Knee Rehabilitation (BIOQUAD)

17. August 2026 aktualisiert von: Hopitaux de Saint-Maurice

Effet du Biofeedback Par EMG de Surface Sur la levée d'Inhibition du Quadriceps en rééducation Post-opératoire du Genou

Arthrogenic muscle inhibition (AMI) is a common neurological impairment following knee surgery that limits voluntary quadriceps activation and delays functional recovery. Persistent AMI may contribute to muscle weakness, altered gait, and poorer rehabilitation outcomes. Although several rehabilitation strategies have been proposed, no complementary intervention has consistently demonstrated strong evidence for improving AMI.

This prospective single-case experimental study aims to evaluate whether visual biofeedback based on surface electromyography (sEMG) improves quadriceps motor performance during standard rehabilitation. Each participant will complete eight standardized rehabilitation sessions, including four sessions with visual sEMG biofeedback and four sessions without visual feedback. The order of the two conditions will be randomized, allowing each participant to serve as his or her own control.

The primary objective is to determine whether visual sEMG biofeedback improves the accuracy of quadriceps contraction, assessed by the percentage deviation from a predefined target. Secondary objectives include evaluation of motor engagement, motor control, muscle activation, perceived exertion, and pain.

Between three and five adult patients presenting AMI after knee surgery will be included. Because recovery patterns are highly individualized, a Single-Case Experimental Design (SCED) with repeated within-subject measurements has been selected to characterize individual treatment responses while minimizing inter-individual variability

Studienübersicht

Status

Noch keine Rekrutierung

Bedingungen

Intervention / Behandlung

Detaillierte Beschreibung

Arthrogenic muscle inhibition (AMI) is a reflexive neurological response commonly observed after knee surgery. It results from altered afferent input originating from the injured joint, leading to reduced voluntary activation of the quadriceps muscle. AMI contributes to muscle weakness, impaired knee extension, gait abnormalities, and delayed functional recovery. Persistent inhibition may negatively affect long-term rehabilitation outcomes.

Surface electromyography (sEMG) biofeedback provides real-time visual information about muscle activation, enabling patients to voluntarily adjust their contractions during rehabilitation exercises. Previous studies suggest that EMG biofeedback may improve neuromuscular activation and motor learning, although evidence remains limited.

The BIOQUAD study is a prospective, within-subject Single-Case Experimental Design (SCED) conducted in adult patients undergoing rehabilitation after knee surgery who present AMI. This design was selected because of the high inter-individual variability in neuromuscular recovery and the exploratory nature of the study. Each participant acts as his or her own control through repeated measurements under two experimental conditions.

Each participant will complete eight standardized rehabilitation sessions over approximately three weeks:

  • Four sessions with visual sEMG biofeedback.
  • Four sessions without visual feedback while EMG signals are still recorded.
  • The order of conditions will be randomized using a predefined balanced sequence to reduce learning and order effects.

At the beginning of each session, maximal quadriceps activation (EMGmax) will be calibrated using three maximal voluntary contractions. Participants will then perform six standardized contractions targeting 80% of EMGmax, each maintained for five seconds and separated by fifteen seconds of rest.

The primary endpoint is contraction accuracy, defined as the percentage deviation from the target muscle activation level. Secondary outcomes include:

time spent within the target activation zone (±5%);

  • motor latency;
  • maximal EMG activity (EMGmax);
  • motor engagement score;
  • perceived exertion (Borg scale);
  • pain intensity (Numeric Rating Scale). Data will be analyzed using SCED methodology with visual and descriptive analyses focusing on level, trend, variability, and overlap between experimental conditions. Results will primarily be interpreted at the individual participant level before descriptive synthesis across participants.

Studientyp

Interventionell

Einschreibung (Geschätzt)

5

Phase

  • Unzutreffend

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienkontakt

Studieren Sie die Kontaktsicherung

Studienorte

      • Saint-Maurice, Frankreich, 94410
        • Hôpitaux Paris Est Val-de-Marne - Service de rééducation orthopédique et traumatologie
        • Kontakt:
        • Kontakt:

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

  • Erwachsene
  • Älterer Erwachsener

Akzeptiert gesunde Freiwillige

Nein

Beschreibung

Inclusion Criteria:

  • AMI following knee surgery, as classified by the Santi classification system
  • Aged 18 or older
  • Enrolled in or covered by a social security program
  • Able to understand instructions and participate in standardized rehabilitation sessions

Exclusion Criteria:

  • Acute pain.
  • Neurological condition.
  • Skin lesion at the electrode site.
  • Allergy to the electrode.
  • Under legal protective measures such as guardianship or court-ordered protection

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: Zufällig
  • Interventionsmodell: Crossover-Aufgabe
  • Maskierung: Keine (Offenes Etikett)

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: Visual sEMG Biofeedback
Participants perform standardized rehabilitation exercises with real-time visual surface electromyography biofeedback.
Participants perform standardized rehabilitation exercises while receiving real-time visual feedback of quadriceps muscle activity using surface electromyography (sEMG)
Aktiver Komparator: No Visual Biofeedback
Participants perform the same standardized rehabilitation exercises without visual biofeedback. Surface EMG signals are recorded but not displayed to the participant.
Participants perform the same standardized rehabilitation exercises without visual biofeedback. Surface electromyography signals are recorded but are not displayed to the participant.

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Percentage Deviation From the Target Quadriceps Activation Level
Zeitfenster: During each of the 8 rehabilitation sessions, over approximately 3 weeks
The percentage deviation between the quadriceps muscle activation achieved by the participant and the predefined target activation level of 80% of the maximal surface electromyography activity (EMGmax). The measure will be calculated for each contraction performed during sessions with visual sEMG biofeedback and sessions without visual biofeedback. The percentage deviation between the participant's quadriceps muscle activation and the predefined target activation level (80% of EMGmax). Lower values indicate greater contraction accuracy.
During each of the 8 rehabilitation sessions, over approximately 3 weeks

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Time Spent Within the Target Quadriceps Activation Zone
Zeitfenster: During each of the 8 rehabilitation sessions, over approximately 3 weeks
Duration, expressed in seconds, during which quadriceps muscle activation remains within ±5% of the predefined target level of 80% of EMGmax during each contraction. A longer time within the target zone indicates better motor control.
During each of the 8 rehabilitation sessions, over approximately 3 weeks
Quadriceps Motor Latency
Zeitfenster: During each of the 8 rehabilitation sessions, over approximately 3 weeks
Time, expressed in seconds, between the instruction to initiate the contraction and the onset of the quadriceps muscle activation recorded by surface electromyography. A shorter latency indicates a faster motor response.
During each of the 8 rehabilitation sessions, over approximately 3 weeks
Maximal Quadriceps Surface Electromyography Activity
Zeitfenster: At the beginning of each of the 8 rehabilitation sessions, over approximately 3 weeks
Maximum quadriceps muscle activation recorded by surface electromyography during the calibration procedure performed at the beginning of each session. EMGmax is determined from three maximal voluntary contractions lasting 5 seconds each
At the beginning of each of the 8 rehabilitation sessions, over approximately 3 weeks
Pain Intensity Assessed Using a Numeric Rating Scale
Zeitfenster: At the end of each of the 8 rehabilitation sessions, over approximately 3 weeks
Participant-reported pain intensity assessed at the end of each rehabilitation session using an 11-point Numeric Rating Scale ranging from 0 to 10, where 0 indicates no pain and 10 indicates the worst imaginable pain.
At the end of each of the 8 rehabilitation sessions, over approximately 3 weeks
Perceived Exertion Assessed Using the Borg Scale
Zeitfenster: At the end of each of the 8 rehabilitation sessions, over approximately 3 weeks
Participant-reported perceived exertion assessed at the end of each rehabilitation session using the Borg CR10 Scale (range: 0-10). Higher scores indicate greater perceived exertion.
At the end of each of the 8 rehabilitation sessions, over approximately 3 weeks

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Ermittler

  • Hauptermittler: Sylvain SB BELOT, MD, Hôpitaux Paris Est Val-de-Marne (HPEVM)

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Geschätzt)

1. August 2026

Primärer Abschluss (Geschätzt)

30. September 2026

Studienabschluss (Geschätzt)

31. Dezember 2026

Studienanmeldedaten

Zuerst eingereicht

24. Juli 2026

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

24. Juli 2026

Zuerst gepostet (Tatsächlich)

30. Juli 2026

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

19. August 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

17. August 2026

Zuletzt verifiziert

1. August 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Zusätzliche relevante MeSH-Bedingungen

Andere Studien-ID-Nummern

  • 2026-A00944-47

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

NEIN

Beschreibung des IPD-Plans

No plan to make individual participant data available to other researchers.

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .